Advertisement
- Abstract
- Materials and Methods
- PART 1 (EFFECT OF MELOXICAM AND PHENYLBUTAZONE ON RENAL FUNCTION)
- PART 2 (EFFECT OF MELOXICAM AND PHENYLBUTAZONE ON RENAL FUNCTION AFTER THE ADMINISTRATION OF FUROSEMIDE)
- PART 3 (EFFECT OF MELOXICAM AND PHENYLBUTAZONE ON RENAL RESPONSES TO DOBUTAMINE INFUSION)
- PART 4 (EFFECT OF MELOXICAM AND PHENYLBUTAZONE ON RENAL RESPONSES TO EXERCISE OF MODERATE INTENSITY)
- PART 5 (URINE FLOW RATE AND CREATININE CLEARANCE AT REST)
- Results
- Discussion
- ABBREVIATIONS
- References
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1. Fu JY, Masferrer JL, Seibert K, et al. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 1990; 265: 16737–16740.
-
2. Xie WL, Chipman JG, Robertson DL, et al. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci U S A 1991; 88: 2692–2696.
-
3. Chandrasekharan NV, Dai H, Roos KL, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A 2002; 99: 13926–13931.
-
4. Harris RC, McKanna JA, Akai Y, et al. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 1994; 94: 2504–2510.
-
5. Cheng HF, Wang JL, Zhang MZ, et al. Angiotensin II attenuates renal cortical cyclooxygenase-2 expression. J Clin Invest 1999; 103: 953–961.
-
6. Guan Y, Chang M, Cho W, et al. Cloning, expression, and regulation of rabbit cyclooxygenase-2 in renal medullary interstitial cells. Am J Physiol 1997; 273: F18–F26.
-
7. Khan KN, Venturini CM, Bunch RT, et al. Interspecies differences in renal localization of cyclooxygenase isoforms: implications in nonsteroidal antiinflammatory drug-related nephrotoxicity. Toxicol Pathol 1998; 26: 612–620.
-
8. Vio CP, Cespedes C, Gallardo P, et al. Renal identification of cyclooxygenase-2 in a subset of thick ascending limb cells. Hypertension 1997; 30: 687–692.
-
9. Yang T, Singh I, Pham H, et al. Regulation of cyclooxygenase expression in the kidney by dietary salt intake. Am J Physiol 1998; 274: F481–F489.
-
10. Radi ZA. Renal system. In: Comparative pathophysiology and toxicology of cyclooxygenases. Hoboken, NJ: John Wiley & Sons, 2012; 127–179.
-
11. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiological foundations and clinical implications. Am J Med 1999; 106: 13S–24S.
-
12. Smith WL, Sonnenburg WK, Allen ML, et al. The biosynthesis and actions of prostaglandins in the renal collecting tubule and thick ascending limb. Adv Exp Med Biol 1989; 259: 131–147.
-
13. Brater DC. Effects of nonsteroidal anti-inflammatory durgs on renal function: focus on cyclooxygenase-2 selective inhibition. Am J Med 1999; 107: 65S–70S.
-
14. Noble G, Edwards S, Lievaart J, et al. Pharmacokinetics and safety of single and multiple oral doses of meloxicam in adult horses. J Vet Intern Med 2012; 26: 1192–1201.
-
15. Bevis PJR, Bird HA, Lapham G. An open study to assess the safety and tolerability of meloxicam 15 mg in subjects with rheumatic disease and mild renal impairment. Br J Rheumatol 1996; 35: 56–60.
-
16. Dyke TM, Hinchcliff KW, Sams RA. Attenuation by phenylbutazone of the renal effects and excretion of furosemide in horses. Equine Vet J 1999; 31: 289–295.
-
17. Schott HC, Ragle CA, Bayly WM. Effects of phenylbutazone and frusemide on urinary excretory responses to high intensity exercise. Equine Vet J Suppl 1995;(18):426–431.
-
18. Schott HC, Hodgson DR, Bayly WM. Ureteral catheterisation in the horse. Equine Vet Educ 1990; 2: 140–143.
-
19. Bickhardt K, Deegen E, Espelage W. Methods of clinical examination of renal function in horses and reference values of healthy animals. Dtsch Tierarztl Wochenschr 1996; 103: 117–122.
-
20. Wilson KE, Wilcke JR, Crisman MV, et al. Comparison of serum iohexol clearance and plasma creatinine clearance in clinically normal horses. Am J Vet Res 2009; 70: 1545–1550.
-
21. Beretta C, Garavaglia G, Cavalli M. COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and meloxicam: an in-vitro analysis. Pharmacol Res 2005; 52: 302–306.
-
22. Gerring EL, Lees P, Taylor JB. Pharmacokinetics of phenylbutazone and its metabolites in the horse. Equine Vet J 1981; 13: 152–157.
-
23. Lees P, Giraudel J, Landoni MF, et al. PK-PD integration and PK-PD modelling of nonsteroidal anti-inflammatory drugs: principles and applications in veterinary pharmacology. J Vet Pharmacol Ther 2004; 27: 491–502.
-
24. Barden AE, Mahoney DP, Tunney AM, et al. Frusemide releases renin in the rat kidney when prostacyclin synthesis is suppressed. Br J Pharmacol 1984; 82: 493–499.
-
25. Data JL, Rane A, Gerkens J, et al. The influence of indomethacin on the pharmacokinetics, diuretic response and haemodynamics of furosemide in the dog. J Pharmacol Exp Ther 1978; 206: 431–438.
-
26. Schott HC, Hodgson DR, Bayly WM. Hematuria, pigmenturia and proteinuria in exercising horses. Equine Vet J 1995; 27: 67–72.
-
27. Schott HC, Hodgson DR, Bayly WM, et al. Renal responses to high intensity exercise. Equine Exerc Physiol 1991; 3: 361–367.
-
28. McKeever KH, Hinchcliff KW, Schmall LM, et al. Renal tubular function in horses during submaximal exercise. Am J Physiol 1991; 261: R553–R560.
-
29. Gleadhill A, Marlin D, Harris PA, et al. Reduction of renal function in exercising horses. Equine Vet J 2000; 32: 509–514.
-
30. Gleadhill A, Marlin D, Harris PA, et al. Use of a three blood sample plasma clearance technique to measure GFR in horses. Vet J 1999; 158: 204–209.
-
31. Breyer J, Jacobson HR. Molecular mechanisms of diuretic agents. Annu Rev Med 1990; 41: 265–275.
-
32. Passmore AP, Copeland S, Johnston GD. A comparison of the effects of ibuprofen and indomethacin upon renal haemodynamics and electrolyte excretion in the presence and absence of furosemide. Br J Clin Pharmacol 1989; 27: 483–490.
-
33. Miyanoshita A, Terada M, Endou H. Furosemide directly stimulates prostaglandin E2 production in the thick ascending limb of Henle's loop. J Pharmacol Exp Ther 1989; 251: 1155–1159.
-
34. He XR, Greenberg SG, Briggs JP, et al. Effects of furosemide and verapamil on the NaCl dependency of macula densa-mediated renin secretion. Hypertension 1995; 26: 137–142.
-
35. Patrono C, Pugliese F, Ciabattoni G, et al. Evidence for a direct stimulator effect of prostacyclin on renin release in man. J Clin Invest 1982; 69: 231–239.
-
36. Müller FO, Middle MV, Schall R, et al. An evaluation of the interaction of meloxicam with furosemide in patients with compensated chronic cardiac failure. Br J Clin Pharmacol 1997; 44: 393–398.
-
37. Corley KT. Inotropes and vasopressors in adults and foals. Vet Clin North Am Equine Pract 2004; 20: 77–106.
-
38. Gehlen H, Weichler A, Bubeck K, et al. Effects of two different dosages of dobutamine on pulmonary artery wedge pressure, systemic arterial blood pressure and heart rate in anaesthetized horses. J Vet Med A Physiol Pathol Clin Med 2006; 53: 476–480.
-
39. Hellyer PW, Wagner AE, Mama KR, et al. The effects of dobutamine and ephedrine on packed cell volume, total protein, heart rate, and blood pressure in anaesthetized horses. J Vet Pharmacol Ther 1998; 21: 497–499.
-
40. Swanson CR, Muir WW III, Bednarski RM, et al. Hemodynamic responses in halothane-anesthetized horses given infusions of dopamine or dobutamine. Am J Vet Res 1985; 46: 365–370.
-
41. Young LE, Blissitt KJ, Clutton RE, et al. Temporal effects of an infusion of dobutamine hydrochloride in horses anesthetized with halothane. Am J Vet Res 1998; 59: 1027–1032.
-
42. Brousseau D, Desjardins J-F, Jasmin G, et al. Altered coronary and cardiac adrenergic response in the failing hamster heart: role of cyclooxygenase derivatives. Can J Physiol Pharmacol 2002; 80: 218–225.
-
43. Hollis AR, Ousey JC, Palmer L, et al. Effects of norepinephrine and a combined norepinephrine and dobutamine infusion on systemic hemodynamics and indices of renal function in normotensive neonatal Thoroughbred foals. J Vet Intern Med 2006; 20: 1437–1442.
-
44. Tobata D, Takao K, Mochizuki M, et al. Effects of dopamine, dobutamine, amrinone and milrinone on regional blood flow in isoflurane anesthetized dogs. J Vet Med Sci 2004; 66: 1097–1105.
-
45. Heino A, Merasto ME, Koski EMJ, et al. Effects of fluid and dobutamine treatment on renal function during partial superior mesenteric artery occlusion and reperfusion. Scand J Urol Nephrol 2002; 36: 5–13.
-
46. Olsen NV, Lund J, Jensen PF, et al. Dopamine, dobutamine and dopexamine: a comparison of renal effects in unanesthetized human volunteers. Anaesthesiology 1993; 79: 685–694.
-
47. Wimmer A, Stanek B, Kubecova L, et al. Effects of prostaglandin E1, dobutamine and placebo on hemodynamic, renal and neurohumoral variables in patients with advanced heart failure. Jpn Heart J 1999; 40: 321–334.
-
48. Cheung PY, Barrington KJ, Bigam D. The hemodynamic effects of dobutamine infusion in the chronically instrumented newborn piglet. Crit Care Med 1999; 27: 558–564.
-
49. Nachar RA, Booth EA, Friedlich P, et al. Dose-dependent hemodynamic and metabolic effects of vasoactive medications in normotensive, anesthetized neonatal piglets. Pediatr Res 2011; 70: 473–479.
-
50. Robel-Tillig E, Knupfer M, Pulzer F, et al. Cardiovascular impact of dobutamine in neonates with myocardial dysfunction. Early Hum Dev 2007; 83: 307–312.
-
51. Good J, Frost G, Dakley CM, et al. The renal effects of dopamine and dobutamine in stable chronic heart failure. Postgrad Med J 1992; 68: S7–S11.
-
52. MacGregor DA, Butterworth JF, Zaloga GP, et al. Hemodynamic and renal effects of dopexamine and dobutamine in patients with reduced cardiac output following coronary artery bypass grafting. Chest 1994; 106: 835–841.
-
53. De Backer D, Zhang H, Manikis P, et al. Regional effects of dobutamine in endotoxic shock. J Surg Res 1996; 65: 93–100.
-
54. McKeever KH, Hinchcliff KW, Schmall LM, et al. Plasma renin activity and aldosterone and vasopressin concentrations during incremental treadmill exercise in horses. Am J Vet Res 1992; 53: 1290–1293.
-
55. Muñoz A, Riber C, Trigo P, et al. Dehydration, electrolyte imbalances and renin-angiotensin-aldosterone-vasopressin axis in successful and unsuccessful endurance horses. Equine Vet J Suppl 2010;(38):83–90.
-
56. Golland LC, Evans DL, Stone GM, et al. Effect of overtraining on plasma cortisol concentrations at rest and in response to exercise and administration of synthetic adrenocorticotropin in Standardbred racehorses. Pferdeheilkunde 1996; 12: 531–533.
-
57. Smith JA, Weidemann MJ. The exercise and immunity paradox: a neuro-endocrine/cytokine hypothesis. Med Sci Res 1990; 18: 749–753.
-
58. Harirforoosh S, Aghazadeh-Habashi A, Jamali F. Extent of renal effect of cyclo-oxygenase-2-selective inhibitors is pharmacokinetic dependent. Clin Exp Pharmacol Physiol 2006; 33: 917–924.
Advertisement
Effects of meloxicam and phenylbutazone on renal responses to furosemide, dobutamine, and exercise in horses
Abstract
Objective—To compare the effects of 2 NSAIDs (phenylbutazone and meloxicam) on renal function in horses.
Animals—9 Thoroughbred or Standardbred mares (mean ± SD age, 5.22 ± 1.09 years [range, 2 to 12 years]; mean body weight, 470 ± 25 kg [range, 442 to 510 kg]).
Procedures—A randomized blinded placebo-controlled crossover study was conducted to examine the effects of treatment with phenylbutazone, meloxicam, or a placebo (control solution) on renal responses to the administration of furosemide, dobutamine, and exercise (15 minutes at 60% of maximum heart rate). Renal function was assessed by use of bilateral ureteral catheterization for simultaneous determination of creatinine clearance, sodium excretion, and urine flow rate.
Results—Both phenylbutazone and meloxicam attenuated diuresis and natriuresis and reduced glomerular filtration rate, compared with results for the control solution, when horses were treated with furosemide. Mean arterial blood pressure, urine flow rate, and glomerular filtration rate were increased during or after (or both) dobutamine infusion. Both NSAIDs reduced urine flow rate and sodium excretion associated with dobutamine infusion and exercise but had no effect on glomerular filtration rate.
Conclusions and Clinical Relevance—Responses to meloxicam, a cyclooxygenase (COX)-2 preferential agent, appeared comparable to those detected after phenylbutazone treatment, which suggested that COX-2 was the mediator of prostanoid-induced changes to renal function in horses and indicated that COX-2–preferential agents would be likely to have adverse renal effects similar to those for nonselective COX inhibitors in volume-depleted horses.
Contributor Notes
Presented in abstract form at the American College of Veterinary Internal Medicine Forum, New Orleans, June 2012.
The authors thank Kate Burnheim and Rhys Duncan for technical assistance and Kristie Hann for assistance with measurement of creatinine concentrations.
Powered by PubFactory